Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/89815
標題: Effect of ultrasonic water extracts of Cordyceps cicadae and Acremonium sp. mycelium (AH888) on cisplatin-induced acute kidney injury in rats
野生蟬花 (Cordyceps cicadae) 子實體與頂孢黴真菌屬 (Acremonium sp.) 菌絲體 (AH888) 超音波水萃取物對順鉑誘發大鼠急性腎損傷之影響
作者: Ming-Chien Wang
王明乾
關鍵字: Cisplatin;Cordyceps cicadae;Acremonium sp;acute kidney injury;順鉑;蟬花;頂孢黴真菌屬;腎損傷
引用: 台灣腎臟醫學會 。 The Taiwan Society of Nephrology. http://www.tsn.org.tw/。2006。 台灣行政院衛生署國民健康局 。 http://www.mohw.gov.tw/CHT/Ministry/Index.aspx。2010。 王海穎、陳以平。陳以平教授巧用蟬花經驗。中國中醫藥信息雜誌 2000,7:10,71。 王琪、劉作易。藥用真菌蟬花的研究進展。 中草藥 2002,34:4, 469-471。 王硯、趙小京、唐法娣。蟬花藥理作用初步探討。浙江中醫雜誌 2001, 36(5):219-220。 朱戎、陳以平、鄧躍毅。固態培養蟬花菌絲延緩腎小球硬化作用及其機制的實驗研究。中國中西醫結合腎病雜誌。2005,6:2,70-74。 朱戎、陳以平、鄧躍毅。液體培養蟬花菌絲對 5/6 腎切除大鼠腎小球 硬化的干預作用。上海中醫藥雜誌 2010,44:5,4-8。 李春如、吳茜茜、顏景華、樊美珍。李增智幾種蟲草無性型及其相關 真菌 SOD 比較研究。安徽農業大學學報 2006,33:1,90-93。 余文娟、許明敏、潘麗輝、樊有賦、陳哗。蟬花多醣超聲波輔助提取 工藝的優化。湖北農業科學 2012,51:20,4598-4600。 宋玉良、宋捷民、嚴建偉。高壓液相色譜法測定蟬花中腺苷含量。中 藥新藥與臨床藥理 2000,11:6,367。 宋捷民、朱英。蟬花對小鼠血糖及造血功能影響。中華中醫藥學刊2007,25:6,1144-1145。 金麗琴、呂建新、袁謙、金晶、陳秀芳。蟬擬青黴對大鼠免疫功能和血液生化指標的影響。溫州醫學院學報 2001,31:6,344-346。 金周慧、陳以平、鄧躍毅。蟬花菌絲延緩腎小球硬化的作用機制研究。中國中西醫結合腎病雜誌 2005,3,132-136。 袁建國、程顯好、侯永勤。冬蟲夏草多醣組分及藥理實驗。食品與藥品 2005,7:1A,45-47。 秦葵、陳紅英。蟬花的研究概況。基層中藥雜誌 2002,16:6,54-55。 陳祝安、劉廣玉、胡菽英。蟬花的人工培養及其藥理作用研究。真菌學報 1993,12:2,138-144。 陳萬群、陳古榮。冬蟲夏草代替品研究進展。中草藥 1994,25:5,269-271。 陳祝安。蟲草真菌蟬擬青黴的研究。真菌學報 1991,10:4,280。 華巍巍、趙嵐、蘇新。冬蟲夏草和蟬花的多糖成分比較。現代應用藥學1989,6:5,13-14。 梁紅卉、程舟、陽曉伶、李珊、丁祖泉、周銅水、張文駒、陳家寬。HPLC 定量分析冬蟲夏草的主要核苷類有效成份。中藥材 2008,31:1,58-61。 閔暘、戚蓓茵、謝煒。蟬花菌絲體抗腎功能衰竭藥效學研究。中國藥理通訊 2004,21:3,19。 葛飛、夏成潤、李春如、丁婷、邵穎、樊美珍。蟬擬青黴菌絲體與天然蟬花中化學成份的比較分析。菌物學報 2007,26:1,68-75。 鄭景文、蕭哲志。探討氧化態低密度脂蛋白與 phenytoin 對小膠質細胞產生誘發型一氧化氮合成酵素之影響。臺北醫學大學藥理學研究所 2007。 賴寧洪、阮桂平、謝友蓮、陳浩桉。冬蟲夏草及其類似品的 HPLC 指紋特征分析。中藥材 2008,31:8,1142-1145。 盧婉妃、徐佳丹、許閃閃、袁強。蟬花 HPLC 指紋圖譜的研究。浙江中醫藥大學學報 2013,37:5,601-605。 劉義聰。綠茶多酚減緩大鼠以 cisplatin 引發之急性腎衰竭。國立中山大學生物科學系研究所 2010。 劉森琴、溫魯、夏敏、蔣寧。人工培育蟬花的活性成分含量測定。安徽農業科學 2008,36:2,429-467。 劉廣玉、胡菽英。天然蟬花和人工培養品鎮靜陣痛作用的比較。現代應用藥學 1991,8:2,5-8。 劉玉寧、陳以平、趙宗江。蟬花菌絲抗單側輸尿管結紮大屬腎小管間質纖維化的研究。 中華醫學會腎臟病學分會論文彙編 2004,321-223。 遲秋陽、陳寶驥、陽曉華。蟬花多醣的提取及其免疫藥理作用的研究。軍隊醫藥雜誌 1996,6:5,44。 Barnes, P.J.; Karin, M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. The New England Journal of Medicine 1997,336,1066-1071. Bellomo, R.; Wan, L.; Langenberg, C.; May, C. Septic acute kidney injury: new concepts. Nephron. Experimental Nephrology 2008,109, 95-100. Bolis, G.; Favalli, G.; Danese, S.; Zanaboni, F.; Mangili, G.; Scarabelli, C.; Tateo, S.; Valsecchi, M.G.; Scarfone, G.; Richiardi, G.; Frigerio, L.; Melpignano, M.; Villa, A.; Parazzini, F. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. Journal of Clinical Oncology : 1997,15,1938-1944. Brenner, B.M.; Meyer, T.W.; Hostetter, T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. The New England Journal of Medicine 1982,307, 652-659. Camano, S.; Lazaro, A.; Moreno-Gordaliza, E.; Torres, A.M., de Lucas, C.; Humanes, B.; Lazaro, J.A.; Milagros Gomez-Gomez, M.; Bosca, L.; Tejedor, A. Cilastatin attenuates cisplatin-induced proximal tubular cell damage. The Journal of Pharmacology and Experimental Therapeutics2010,334,419-429. Camp, E.R.; Li, J.; Minnich, D.J.; Brank, A.; Moldawer, L.L.; MacKay, S.L.; Hochwald, S.N. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. Journal of the American College of Surgeons 199:249-258. Chen, S., Gong, J., Liu, F., Mohammed, U., 2000. Naturally occurring polyphenolic antioxidants modulate IgE-mediated mast cell activation. Immunology 2004,100,471-480. Cherry, S.M.; Hunt, P.A.; Hassold, T.J. Cisplatin disrupts mammalian spermatogenesis, but does not affect recombination or chromosome segregation. Mutation Research 2004,564, 115-128. Chien, C.T.; Lee, P.H.; Chen, C.F.; Ma, M.C.; Lai, M.K.; Hsu, S.M. De novo demonstration and co-localization of free-radical production and apoptosis formation in rat kidney subjected to ischemia/reperfusion. Journal of the American Society of Nephrology : 2001, 12,973-982. Choi, C.H.; Cha, Y.J.; An, C.S.; Kim, K.J.; Kim, K.C.; Moon, S.P.; Lee, Z.H.; Min, Y.D. Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein. Cancer Cell International 2004,4,6-11. Ciarimboli, G.; Ludwig, T.; Lang, D.; Pavenstadt, H.; Koepsell, H.; Piechota, H.J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. The American Journal of Pathology 2005, 167, 1477-1484. Collins, T.; Read, M.A.; Neish, A.S.; Whitley, M.Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB journal : official publication of the Federation of American Societies for Experimental. Biology 1995, 9, 899-909. Coppin, C.M.; Gospodarowicz, M.K.; James, K.; Tannock, I.F.; Zee, B.; Carson, J.; Pater, J.; Sullivan, L.D. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996, 14, 2901-2907. Cross, C.E.; van der Vliet, A.; Louie, S.; Thiele, J.J.; Halliwell, B. Oxidative stress and antioxidants at biosurfaces: plants, skin, and respiratory tract surfaces. Environmental health perspectives 106 (Suppl) 1998, 5, 1241-1251. Crozier, A.; Burns, J.; Aziz, A.A.; Stewart, A.J.; Rabiasz, H.S.; Jenkins, G.I.; Edwards, C.A.; Lean, M.E. Antioxidant flavonols from fruits, vegetables and beverages: measurements and bioavailability. Biological Research 2000, 33, 79-88. Cummings, B.S.; Schnellmann, R.G. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. The Journal of Pharmacology and Experimental Therapeutics 2002, 302, 8-17. Dagher, P.C.; Herget-Rosenthal, S.; Ruehm, S.G.; Jo, S.K.; Star, R.A.; Agarwal, R.; Molitoris, B.A. Newly developed techniques to study and diagnose acute renal failure. Journal of the American Society of Nephrology : 2003, 14, 2188-2198. de Vries, B.; Walter, S.J.; von Bonsdorff, L.; Wolfs, T.G.; van Heurn, L.W.; Parkkinen, J.; Buurman, W.A. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation 2004, 77, 669-675. Devarajan, P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr2005, 17, 193-199. Devarajan, P. Update on mechanisms of ischemic acute kidney injury. Journal of the American Society of Nephrology : 2006, 17, 1503-1520. Devarajan, P.; Mishra, J.; Supavekin, S.; Patterson, L.T.; Steven Potter, S. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 2003, 80, 365-376. Doi, K.; Suzuki, Y.; Nakao, A.; Fujita, T.; Noiri, E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney International 2004, 65, 1714-1723. Durairaj, L.; Schmidt, G.A. Fluid therapy in resuscitated sepsis: less is more. Chest 2008, 133, 252-263. Einhorn, L.H. Curing metastatic testicular cancer. Proceedings of the National Academy of Sciences of the United States of America 2002, 99, 4592-4595. Fatima, S.; Arivarasu, N.A.; Mahmood, R. Vitamin C attenuates cisplatin-induced alterations in renal brush border membrane enzymes and phosphate transport. Human & Experimental Toxicology 2002, 26, 419-426. Fernandez-Silva, F.; Capilla, J.; Mayayo, E.; Sutton, D.; Guarro, J. Experimental murine acremoniosis: an emerging opportunistic human infection. Medical Mycology 2014, 52, 29-35. Fernandez-Silva, F.; Capilla, J.; Mayayo, E.; Sutton, D.A.; Hernandez, P.; Guarro, J. Evaluation of the efficacies of Amphotericin B, Posaconazole, Voriconazole, And Anidulafungin in a murine disseminated infection by the emerging opportunistic Fungu Sarocladium (Acremonium) kiliense. Antimicrobial Agents and Chemotherapy 2013, 57, 6265-6269. Filipski, K.K.; Loos, W.J.; Verweij, J.; Sparreboom, A. Interaction of Cisplatin with the human organic cation transporter 2. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14, 3875-3880. Francescato, H.D.; Costa, R.S.; Scavone, C.; Coimbra, T.M. Parthenolide reduces cisplatin-induced renal damage. Toxicology 2007, 230, 64-75. Gatzemeier, U.; von Pawel, J.; Gottfried, M.; ten Velde, G.P.; Mattson, K.; de Marinis, F.; Harper, P.; Salvati, F.; Robinet, G.; Lucenti, A.; Bogaerts, J.; Gallant, G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000, 18, 3390-3399. Ghosh, S.; May, M.J.; Kopp, E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998, 16, 225-260. Gilmore, T.D. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999, 18, 6842-6844. Gilmore, T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006, 25,6680-6684. Gogvadze, V.; Orrenius, S. Mitochondrial regulation of apoptotic cell death. Chemico-biological Iteractions 2006, 163, 4-14. Green, S.J.; Scheller, L.F.; Marletta, M.A.; Seguin, M.C.; Klotz, F.W.; Slayter, M.; Nelson, B.J.; Nacy, C.A. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunology Letters 1994, 43, 87-94. Hanigan, M.H.; Gallagher, B.C.; Taylor, P.T.; Jr.; Large, M.K. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Research 1994, 54, 5925-5929. Hartmann, J.T.; Fels, L.M.; Knop, S.; Stolt, H.; Kanz, L.; Bokemeyer, C. A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Investigational New Drugs 2000, 18, 281-289. Hartmann, J.T.; Lipp, H.P. Toxicity of platinum compounds. Expert Opinion on Pharmacotherapy 2003, 4, 889-901. Holzer, A.K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Molecular Pharmacology 2004, 66, 817-823. Honda, G.; Matsuda, A.; Zushi, M.; Yamamoto, S.; Komatsu, K. Heterologous protein production in Acremonium chrysogenum: expression of bacterial cephalosporin C acylase and human thrombomodulin genes. Bioscience, biotechnology, and biochemistry 1997, 61, 948-955. Hoskins, P.; Eisenhauer, E.; Vergote, I.; Dubuc-Lissoir, J.; Fisher, B.; Grimshaw, R.; Oza, A.; Plante, M.; Stuart, G.; Vermorken, J. Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology : 2000, 18, 4038-4044. Ignarro, L.J. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 1990, 16, 477-483. Ishida, S.; Lee, J.; Thiele, D.J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences of the United States of America 2002, 99, 14298-14302. Jo, S.K.; Cho, W.Y.; Sung, S.A.; Kim, H.K.; Won, N.H. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney International 2005, 67, 458-466. Kaushal, G.P.; Kaushal, V.; Hong, X.; Shah, S.V. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney International 2001, 60, 1726-1736. Kim, S.J.; Cho, Y.W.; Seo, S.W.; Kim, S.J.; Yoo, J.M. Clinical experiences in fungal keratitis caused by Acremonium. Clinical Ophthalmology 2014, 8, 283-287. Kinsey, G.R.; Li, L.; Okusa, M.D. Inflammation in acute kidney injury. Nephron. Experimental Nephrology 2008, 109, e102-107. Kwon, O.; Nelson, W.J.; Sibley, R.; Huie, P.; Scandling, J.D.; Dafoe, D.; Alfrey, E.; Myers, B.D. Backleak, tight junctions, and cell- cell adhesion in postischemic injury to the renal allograft. Journal of Clinical Invest 1998, 101, 2054-2064. Lee, D.B.; Huang, E.; Ward, H.J. Tight junction biology and kidney dysfunction. Journal of the American Physiol Renal Physiol 2006, 290, F20-34. Loehrer, P.J.; Sr.;Gonin, R.; Nichols, C.R.; Weathers, T.; Einhorn, L.H.; Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. Journal of clinical oncology 1998, 16, 2500-2504. Ludwig, T.; Riethmuller, C.; Gekle, M.; Schwerdt, G.; Oberleithner, H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney international 2004, 66, 196-202. Menshikova, E.B.; Zenkov, N.K.; Reutov, V.P. Nitric oxide and NO-synthases in mammals in different functional states. Biochemistry. (Biokhimiia) 2000, 65, 409-426. Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins 2010, 2, 2490-2518. Munchausen, L.L. The chemical and biological effects of cis-dichlorodiammineplatinum (II), an antitumor agent, on DNA. Proceedings of the National Academy of Sciences of the United States of America 1974, 71, 4519-4522. Nathan, C.; Xie, Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78, 915-918. National Kidney Foundation. 2002. (http://www.kidney.org/). Nowak, G. Protein kinase C-alpha and ERK1/2 mediate mitochondrial dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis in renal cells. The Journal of biological chemistry 277, 43377-43388. 2002, Perkins, N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nature Reviews. Molecular cell biology 2007, 8, 49-62. Peterson, J.C.; Adler, S.; Burkart, J.M.; Greene, T.; Hebert, L.A.; Hunsicker, L.G.; King, A.J.; Klahr, S.; Massry, S.G.; Seifter, J.L. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Annals of internal medicine 1995, 123, 754-762. Pisoni, R.; Ruggenenti, P.; Remuzzi, G. Renoprotective therapy in patients with nondiabetic nephropathies. Drugs 2001, 61, 733-745. Planting, A.S.; Catimel, G.; de Mulder, P.H.; de Graeff, A.; Hoppener, F.; Verweij, J.; Oster, W.; Vermorken, J.B. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Annals of Oncology 1999, 10, 693-700. Pratt, R.E.; Flynn, J.A.; Hobart, P.M.; Paul, M.; Dzau, V.J. Different secretory pathways of renin from mouse cells transfected with the human renin gene. The Journal of Biological Chemistry 1988, 263, 3137-3141. Prozialeck, W.C.; Vaidya, V.S.; Liu, J.; Waalkes, M.P.; Edwards, J.R.; Lamar, P.C.; Bernard, A.M.; Dumont, X.; Bonventre, J.V. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney International 2007, 72, 985-993. Remuzzi, G.; Bertani, T. Pathophysiology of progressive nephropathies. The New England journal of medicine 1998, 339, 1448-1456. Rose, P.G.; Bundy, B.N.; Watkins, E.B.; Thigpen, J.T.; Deppe, G.; Maiman, M.A.; Clarke-Pearson, D.L.; Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. The New England journal of medicine 1999, 340, 1144-1153. Sen, R.; Baltimore, D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986, 47, 921-928. Shackelford, C.; Long, G.; Wolf, J.; Okerberg, C.; Herbert, R. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicologic Pathology 2002, 30, 93-96. Sheikh-Hamad, D.; Cacini, W.; Buckley, A.R.; Isaac, J.; Truong, L.D.; Tsao, C.C.; Kishore, B.K. Cellular and molecular studies on cisplatin-induced apoptotic cell death in rat kidney. Archives of Toxicology 2004, 78, 147-155. Sinha, V.; Vence, L.M.; Salahudeen, A.K. Urinary tubular protein-based biomarkers in the rodent model of cisplatin nephrotoxicity: a comparative analysis of serum creatinine, renal histology, and urinary KIM-1, NGAL, and NAG in the initiation, maintenance, and recovery phases of acute kidney injury. Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2013,61, 564-568. Singbartl, K.; Ley, K. Leukocyte recruitment and acute renal failure. Journal of Molecular Medicine 2004, 82, 91-101. Skaper, S.D.; Fabris, M.; Ferrari, V.; Dalle Carbonare, M.; Leon, A. Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: cooperative effects of ascorbic acid. Free Radical Biology & Medicine 1997, 22, 669-678. Small, D.M.; Coombes, J.S.; Bennett, N.; Johnson, D.W.; Gobe, G.C. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology 2012, 17, 311-321. Sorsa, M.; Hemminki, K.; Vainio, H. Occupational exposure to anticancer drug--potential and real hazards. Mutation Research 1985, 154, 135-149. Srisawasdi, P.; Chaichanajarernkul, U.; Teerakanjana, N.; Vanavanan, S.; Kroll, M.H. Exogenous interferences with Jaffe creatinine assays: addition of sodium dodecyl sulfate to reagent eliminates bilirubin and total protein interference with Jaffe methods. Journal of Clinical Laboratory Analysis 2010, 24, 123-133. Sugihara, K.; Nakano, S.; Koda, M.; Tanaka, K.; Fukuishi, N.; Gemba, M. Stimulatory effect of cisplatin on production of lipid peroxidation in renal tissues. Japanese Journal of Pharmacology 1987, 43, 247-252. Sutton, T.A.; Fisher, C.J.; Molitoris, B.A. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney International 2002, 62, 1539-1549. Taiwan National Health Insurance. 2012. (http://www.nhi.gov.tw/). Tauchi, H.; Tsuboi, K.; Okutomi, J. Age changes in the human kidney of the different races. Gerontologia 1971, 17, 87-97. Tollnick, C.; Seidel, G.; Beyer, M.; Schugerl, K. Investigations of the production of cephalosporin C by Acremonium chrysogenum. Advances in Biochemical Engineering/Biotechnology 2004, 86, 1-45. Townsend, D.M.; Hanigan, M.H. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. The Journal of Pharmacology and Experimental Therapeutics 2002, 300, 142-148. Townsend, D.M.; Tew, K.D.; He, L.; King, J.B.; Hanigan, M.H. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomedicine & Pharmacotherapy (Biomedecine & pharmacotherapie) 2009, 63, 79-85. Vaidya, V.S.; Ford, G.M.; Waikar, S.S.; Wang, Y.; Clement, M.B.; Ramirez, V.; Glaab, W.E.; Troth, S.P.; Sistare, F.D.; Prozialeck, W.C.; Edwards, J.R.; Bobadilla, N.A.; Mefferd, S.C.; Bonventre, J.V. A rapid urine test for early detection of kidney injury. Kidney International 2009, 76, 108-114. Vaidya, V.S.; Ramirez, V.; Ichimura, T.; Bobadilla, N.A.; Bonventre, J.V. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. American Journal of Physiology. Renal Physiology 2006, 290, F517-529. Vinken, P.; Starckx, S.; Barale-Thomas, E.; Looszova, A.; Sonee, M.; Goeminne, N.; Versmissen, L.; Buyens, K.; Lampo, A. Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicologic Pathology 2012, 40, 1049-1062. Wang, D.; Lippard, S.J. Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery 2005, 4, 307-320. Widmann, C.; Gibson, S.; Jarpe, M.B.; Johnson, G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiological Reviews 1999, 79, 143-180. Widmaier, E.P.; Raff, H.; Strang, K,T. Vanderʼs human physiology : the mechanisms of body function, 10ed. The McGraw-Hill Co. 2008, p477-573 Yamaguchi, K.; Ishikawa, T.; Kondo, Y.; Fujisawa, M. Cisplatin regulates Sertoli cell expression of transferrin and interleukins. Molecular and Cellular Endocrinology 2008, 283, 68-75. Yang, G.Y.; Mao, Y.; Zhou, L.F.; Ye, W.; Liu, X.H.; Gong, C.; Lorris Betz, A. Attenuation of temporary focal cerebral ischemic injury in the mouse following transfection with interleukin-1 receptor antagonist. Brain Research. Molecular Brain Research 1999, 72, 129-137. Yao, X.; Panichpisal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: a review. The American journal of the medical sciences 2007, 334, 115-124. Yeh, C.H.; Hsu, S.P.; Yang, C.C.; Chien, C.T.; Wang, N.P. Hypoxic preconditioning reinforces HIF-alpha-dependent HSP70 signaling to reduce ischemic renal failure-induced renal tubular apoptosis and autophagy. Life Sciences 2010, 86, 115-123. Yeomans, E.R.; Hauth, J.C.; Gilstrap, L.C.; 3rd, Strickland, D.M. Umbilical cord pH, PCO2, and bicarbonate following uncomplicated term vaginal deliveries. American Journal of Obstetrics and Gynecology 1985, 151, 798-800. Yonezawa, A.; Masuda, S.; Yokoo, S.; Katsura, T.; Inui, K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). The Journal of Pharmacology and Experimental Therapeutics 2006, 319, 879-886. You, Q.; Yin, X.; Zhao, Y.; Jiang, Z. Extraction and Purification of Polysaccharides from Pine Medicinal Mushroom, Tricholoma matsutake (Higher Basidiomycetes) Fruit Bodies. International journal of medicinal mushrooms 2014, 16, 149-160. Zhou, Y.; Vaidya, V.S.; Brown, R.P.; Zhang, J.; Rosenzweig, B.A.; Thompson, K.L.; Miller, T.J.; Bonventre, J.V.; Goering, P.L. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicological sciences 2008, 101, 159-170.
摘要: 
順鉑 (cisplatin) 在治療卵巢癌、生殖細胞癌、食道癌、肺癌等方面,具有良好的治療效果,但其嚴重的副作用會造成腎臟近曲小管損傷、腎臟細胞壞死與纖維化,造成慢性腎衰竭。蟬花別名蟲花,是某些蟬若蟲受蟬擬青黴菌 (Paecilomyces cicadae) 寄生後的產物,為一種菌蟲複合體,推測具有改善腎臟疾病之潛力,故本研究擬探討野生蟬花 (Cordyceps cicadae)子實體超音波水萃取物 (ultrasonic water extracts of Cordyceps cicadae,WECC) 與頂孢黴真菌屬 (Acremonium sp.) 菌絲體 (AH888) 超音波水萃取物 (ultrasonic water extracts of Acremonium sp. mycelium, WEAM) 對順鉑誘發 Sprague-Dawley (SD) 大鼠急性腎損害之影響。五週齡 SD 大鼠分成Blank 空白組 (B)、cisplatin 傷害組 (C)、cisplatin 加 WECC組 (CC) 與cisplatin 加 WEAM組 (CA) 共四組。分別在第 0、3、6、9、12 與 16 天以腹腔注射 cisplatin (1 mg/kg B.W.) 進行腎損傷誘導。第 17 天起開始連續 28 天管餵各組不同實驗藥物,劑量參考以人體每日建議摄取量 9 公克(蟬花)、3 公克 (AH888) 換算為大鼠管餵量 (蟬花:930 mg/kg;AH888:310 mg/kg),cisplatin 傷害組也餵食等量體積的 0.9% 生理食鹽水。實驗結果顯示,WECC 與 WEAM 對順鉑誘導大鼠血液中尿素氮 (BUN)、肌酸酐 (creatinine) 與尿液中蛋白尿含量無顯著抑制效果;WECC 與 WEAM大鼠存活率及組織病理分析腎臟損傷亦無明顯改善作用;而 WEAM 對降綜合低腎臟損傷分子-1 (kidney injury molecule-1, KIM-1) 有顯著抑制效果。以上結果,WEAM 與 WECC 僅可些稍緩解順鉑造成的腎臟損傷。

Cisplatin is one of potent tumor suppressor compounds, by its main mechanism of action of DNA cross-linked inhibition of cell replication and division, resulting in tumor cell apoptosis and necrosis. However, the limit of application of cisplatin on clinical treatment occurred due to its side effects, such as kidney injury. Cordyceps cicadae is a fungus which attacks insects or a fungus insect complex including cicada larvae by Paecilomyces cicadae. Moreover, Cordyceps cicadae may possess potential to improve kidney disease. This study was aimed to evaluate the effect of ultrasonic water extracts of Cordyceps cicadae (WECC) and ultrasonic water Acremonium sp. mycelium (WEAM) on SD rats with cisplatin-induced acute kidney injury. Rats were intraperitoneally injection with cisplatin (1 mg/kg of B.W.) on the 1st day, 3th day, 6th day, 9th day, 12th day, 16th day. On day 17, 0.9% saline by oral gavage (C group), WEAM at 310 mg/kg of B.W. (CA group) and WECC at 930 mg/kg of B.W. (CC group) were treated until the 44th day. The results showed that the levels of serum blood urea nitrogen (BUN), creatinine and urinary protein, survival rate and histological examination showed no significant difference in WECC and WEAM groups compared to the cisplatin group. However, a slight decrease of kidney injury molecular-1 (KIM-1) level in kidney tissues was observed in the WEAM treated rats. In conclusion, WECC and WEAM might be a limited improve on renal damage caused by cisplatin.
URI: http://hdl.handle.net/11455/89815
Rights: 不同意授權瀏覽/列印電子全文服務
Appears in Collections:食品暨應用生物科技學系

Files in This Item:
File Description SizeFormat Existing users please Login
nchu-103-5101043017-1.pdf2.67 MBAdobe PDFThis file is only available in the university internal network    Request a copy
Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.